CBD and Pain: What the Evidence Shows and What It Does Not
CBD is heavily marketed for pain, arthritis, nerve pain and recovery. The evidence is more complicated than the marketing.
What Research Includes
Cannabinoid pain studies use different products, including THC-containing medicines, nabiximols, purified CBD and mixed cannabis preparations. Results from one product cannot automatically be transferred to another.
CBD-Only Evidence
Evidence for CBD alone in chronic pain remains limited and inconsistent. Claims that retail CBD reliably reduces neuropathic pain, arthritis pain or inflammation should therefore be avoided.
Opioid-Sparing Claims
Some observational research has explored cannabinoid use alongside opioids. These studies do not establish that retail CBD safely allows patients to reduce opioid doses. Any opioid change should be clinician-supervised.
Topicals vs Oral Products
Topical CBD products are applied to the skin; oral oils and capsules have different absorption and interaction profiles. Neither route should be described as guaranteed “targeted” or “systemic” pain relief without product-specific evidence.
Safety and Medicine Interactions
CBD can cause side effects and interact with medicines. People using anticoagulants, anti-seizure medicines, sedatives or other prescription drugs should ask a doctor or pharmacist before use.
Regulatory Context in Malta
The status of a CBD product depends on its format, ingredients, intended use and claims. A retail CBD product is not automatically a licensed pain medicine.
Bottom Line
CBD remains an active area of pain research, but broad consumer claims about pain relief, inflammation reduction or opioid replacement go beyond the evidence for ordinary retail products.
